On the Frontlines of AML/ALL
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are among the most complex and aggressive hematologic malignancies. That’s why our On the Frontlines of AML/ALL series brings together leading hematologists and oncologists to examine emerging data, evolving treatment paradigms, and clinical strategies for optimizing outcomes across the continuum of AML and ALL care.
Updates in AML Care: Evolving ASH Guidelines for Older Adults
On the Frontlines of AML/ALLUpdates in AML Care: Evolving ASH Guidelines for Older Adults
Venetoclax and Palbociclib in AML: Exploring New Findings
On the Frontlines of AML/ALLVenetoclax and Palbociclib in AML: Exploring New Findings
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
On the Frontlines of AML/ALLAdvancing Relapse Prediction in Pediatric AML Through Genomic MRD
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
On the Frontlines of AML/ALLNeighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
Optimizing Care for Older Adults With FLT3-Mutated AML
On the Frontlines of AML/ALLOptimizing Care for Older Adults With FLT3-Mutated AML
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
Project Oncology®Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
- advertisement
